Farrimond LE Roberts E & McShane R 2012 Memantine and cholinesterase inhibitor combination therapy for Alzheimers disease: a systemic review BMJ Open vol. 2 no. 3 pp. 917-923.
This article strives to examine the comparison in the efficacy between the use of cholinesterase monotherapy for the treatment of Alzheimers disease and its use in combination with memantine for the treatment and management of the same. The authors further examine what impacts using unpublished data in their findings would have on their final results. The study was carried out on patients in the moderate to severe stages of Alzheimers disease. Combination therapy of memantine and cholinesterase has been widely suggested to be efficient in the alleviation of Alzheimers disease symptoms. However in this article the authors suggest that the benefits of using the combination therapy are very minimal at six months and that there was no effect on patients functions whatsoever. Therefore the study does not demonstrate sufficient clinical relevance of the effects of the combination therapy. Throughout their investigation Farrimond and his friends demonstrate the view point that even at one year; the combination therapy does not show any superiority over monotherapy on moderate to severe Alzheimers disease. This article lacks reliable evidence to support its claims and therefore may not be very useful in answering the research question in this assignment. Furthermore it does not discuss the issue of safety and tolerability of the combination therapy which are key factors in the research question. However this article may be containing useful information for the analysis of the comparison between the use of monotherapy and combination therapy in Ads management although it will require some additional research and adaptation in order to qualify to be used in this assignment.